Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -541.5%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $991809 | $2M | $509630 | — | — | — | — |
| Enterprise Value | $-1838077 | $-1216400 | $10M | — | — | — | — |
| P/E Ratio → | -0.05 | — | — | — | — | — | — |
| P/S Ratio | 0.07 | 0.11 | 0.05 | — | — | — | — |
| P/B Ratio | 0.13 | 0.30 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.08 | 0.93 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 50.3% | 50.3% | 68.9% | 66.5% | 75.8% | 80.7% | 80.3% |
| Operating Margin | -65.6% | -65.6% | -596.4% | -32.5% | -26.3% | 3.4% | 5.9% |
| Net Profit Margin | -100.6% | -100.6% | -553.7% | -65.3% | -13.1% | 6.5% | 3.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -541.5% | -541.5% | — | — | -1.5% | 0.8% | 42.1% |
| ROA | -69.4% | -69.4% | -554.9% | -220.2% | -1.4% | 0.8% | 9.5% |
| ROIC | -121.6% | -121.6% | -1749.8% | — | -2.2% | 0.3% | — |
| ROCE | -268.0% | -268.0% | -6327.9% | — | -2.9% | 0.4% | 65.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.45 | 0.45 | — | — | — | — | 0.22 |
| Debt / EBITDA | — | — | — | — | — | — | 0.33 |
| Net Debt / Equity | — | -0.52 | — | — | — | -0.01 | -1.05 |
| Net Debt / EBITDA | — | — | — | — | — | -1.97 | -1.59 |
| Debt / FCF | — | — | — | — | — | — | -0.81 |
| Interest Coverage | -4.21 | -4.21 | -22.15 | -0.82 | -11.62 | — | — |
Net cash position: cash ($5M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.51 | 0.51 | 0.16 | 0.16 | 0.29 | 6.62 | 0.70 |
| Quick Ratio | 0.51 | 0.51 | 0.16 | 0.16 | 0.29 | 6.62 | 0.70 |
| Cash Ratio | 0.32 | 0.32 | 0.02 | 0.02 | 0.09 | 4.13 | 0.37 |
| Asset Turnover | — | 0.65 | 0.52 | 7.16 | 2.44 | 0.06 | 2.50 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 62.94 | 78.74 | 39.78 | 22.29 | 14.23 | 35.35 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $20M | $10M | $10M | $10M | $10M | $10M |
Insufficient liquidity for operations
Based on current market data, VSEEW trades at a P/S multiple of 0.07, a figure that suggests the market is heavily discounting the company's future revenue potential due to persistent net losses and the absence of a clear path to profitability in the near term.
The extremely low P/S ratio relative to broader healthcare IT peers indicates that investors are pricing in significant execution risk rather than growth. This valuation level appears to reflect a market consensus that the current business model requires substantial capital restructuring to survive.
As reported in recent financial statements, VSEEW's ROIC has consistently remained in negative territory, reaching -28.1% in 2026Q1, which highlights a fundamental inability to generate returns on invested capital that exceed the company's cost of funding its clinical deployment operations.
The persistent decay in ROIC suggests that the capital deployed into hospital-facing infrastructure is not yielding the expected operational leverage. This trend warrants further investigation into whether the company's high-touch implementation model is inherently capital-intensive and incapable of scaling efficiently.
According to historical data, VSEEW's DPO has fluctuated significantly, reaching 215 days in 2026Q1, which suggests that the company may be relying on extended supplier payment terms to manage its precarious liquidity position amidst a challenging revenue collection environment.
The high DPO relative to industry norms may indicate that the company is stretching its payables to preserve cash, a strategy that could jeopardize supplier relationships. Investors should monitor whether this reliance on vendor financing is sustainable as the company attempts to scale its iDoc platform.
Based on the 2026Q1 balance sheet, VSEEW's current ratio of 0.41 indicates a severe mismatch between short-term assets and immediate obligations, leaving the firm with a limited buffer to navigate the high-cost procurement cycles inherent in the medical information services sector.
This liquidity profile suggests that the company is highly vulnerable to even minor disruptions in cash inflows from hospital contracts. The lack of a robust quick ratio implies that the firm may be forced to seek dilutive financing to maintain its current operational footprint.
Market participants often over-rely on top-line revenue growth as a proxy for success, yet for VSEEW, this metric obscures the underlying margin compression and the high cost of acquiring hospital system clients, which currently outpaces the value generated by new deployments.
Analysts should prioritize the 'active provider seat' count and hardware-to-software attachment ratios over headline revenue growth to assess true business health. Focusing on revenue alone ignores the reality that current growth is likely being purchased at the expense of long-term shareholder value.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VSEEW stock.
VSee Health, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
VSee Health, Inc.'s return on equity (ROE) is -541.5%. The historical average is 13.8%.
Based on historical data, VSee Health, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
VSee Health, Inc. has 50.3% gross margin and -65.6% operating margin.